Evidence map›Paper›PMID 36484300›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection.

Sara H Browne, Florin Vaida, Anya Umlauf, Amanda J Tucker, Terrence F Blaschke, Constance A Benson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sara H BrowneDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
Florin VaidaDepartment of Family Medicine and Public Health, University of California San Diego, La Jolla, California, USA.
Anya UmlaufDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Amanda J TuckerDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
Terrence F BlaschkeDepartment of Medicine, Stanford University, Stanford, California, USA.
Constance A BensonDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
University of California, San Diego · USStanford University · US

Funding

A Novel Wireless Ingestible Sensor System for Measurement of Medication Adherence in HIV Treatment and PreventionR01MH110057 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN, BROWNE, SARA H. · 2015 to 2019
$5.9M
NIMH NIH HHS MH110057NIMH NIH HHS R01 MH110057
6 · The paper itself

Abstract

backgroundTimely, accurate adherence data may support oral pre-exposure prophylaxis (PrEP) success and inform prophylaxis choice. We evaluated a Food and Drug Administration (FDA)-approved digital health feedback system (DHFS) with ingestible-sensor-enabled (IS) tenofovir-disoproxil-fumarate plus emtricitabine (Truvada®) in persons starting oral PrEP.

methodsHuman immunodeficiency virus (HIV)-negative adults were prescribed IS-Truvada® with DHFS for 12 weeks to observe medication taking behavior. Baseline demographics, urine toxicology, and self-report questionnaires were obtained. Positive detection accuracy and adverse events were computed as percentages, with Kaplan Meier Estimate for persistence-of-use. In participants persisting ≥28 days, adherence patterns (taking and timing) were analyzed, and mixed-effects logistic regression modeled characteristics associated with treatment adherence.

resultsSeventy-one participants were enrolled, mean age 37.6 years (range 18-69), 90.1% male, 77.5% White, 33.8% Hispanic, 95.8% housed, and 74.6% employed. Sixty-three participants (88.7%) persisted ≥28 days, generating 4987 observation days, average 79.2 (29-105). Total confirmed doses were 86.2% (95% confidence interval [CI] 82.5, 89.4), decreasing over time, odds ratio (OR) 0.899 (95% CI .876, .923) per week, P < .001; 79.4% (95% CI 66.7%, 87.3%) of participants had ≥80% adherence. Pattern analysis showed days without confirmed doses clustered (P = .003); regular dose timing was higher among participants with ≥80% confirmed doses (0.828, 95% CI .796 to .859) than among those with <80% (0.542, 95% CI95 .405 to .679) P < .001. In multi-predictor models, better adherence was associated with older age, OR 1.060 (95% CI 1.033, 1.091) per year, P < .001; negative vs positive methamphetamine screen, OR 5.051 (95% CI 2.252, 11.494), P < .001.

conclusionsDHFS with IS-Truvada® distinguished adherent persons from those potentially at risk of prophylactic failure. Ongoing methamphetamine substance use may impact oral PrEP success.

Indexed as

Anti-HIV AgentsHIV InfectionsMethamphetaminePre-Exposure ProphylaxisAdolescentAdultAgedEmtricitabineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationFemaleHomosexuality, MaleHumansMaleMedication AdherenceMiddle AgedYoung AdultAnti-HIV AgentsEmtricitabineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationMethamphetamineadherenceHIV prophylaxisingestible-sensorreal-time patterns

Identifiers

PMID36484300
PMCPMC10202440
OpenAlexW4226228333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.